Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
There are two drugs involved in this study. Sunitinib (Sutent(R)) is approved by the Food and
Drug Administration (FDA) for the treatment of advanced renal cell (kidney) cancer and
gastrointestinal stromal tumors. Sunitinib is thought to work by blocking the growth of blood
vessels into tumors; reducing the blood supply to tumors can slow their growth and sometimes
causes the tumors to shrink. Sirolimus has been approved by the FDA to prevent the body from
rejecting organ transplants. Sirolimus is being tested for its effects against cancer because
it can slow the growth of some tumors in animal models. Sirolimus is thought to slow cancer
growth in these animal models both by direct effects on the tumor cells, and also by blocking
production of growth factors that stimulate production of blood vessels. We hope that the
combined use of these two drugs will have better anti-cancer effects than either agent alone.
This study is designed to find out if different doses of Sirolimus combined with a standard
dose of Sutent are safe and well tolerated. Additionally, it is hoped to gain knowledge about
the way that Sutent(R) in combination with sirolimus affects the blood vessels produced by
cancer.